NP-G2-044 (Prilukae), a novel oral fascin inhibitor, has earned orphan drug designation (ODD) from the FDA for the treatment ...
During the J.P. Morgan Healthcare Conference, VIVUS will share key highlights from 2025, demonstrating our commitment to advancing innovative clinical therapies across a variety of conditions,” said ...
In a small pilot study of patients with advanced pancreatic cancer, early access to medical cannabis shows promise in the ...
The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback